# Primary renal lymphoma in a uremic patient

**Authors:** Qiqi Qi, Manying Wen, Yicheng Huang, Yueming Liu, Shenghua Yao

PMC · DOI: 10.1093/omcr/omaf026 · Oxford Medical Case Reports · 2025-05-28

## TL;DR

A rare case of primary renal lymphoma in a patient on dialysis is reported, highlighting the importance of accurate diagnosis and treatment for better outcomes.

## Contribution

This paper presents a rare case of primary renal lymphoma in a uremic patient and emphasizes the need for differential diagnosis.

## Key findings

- A 57-year-old woman on hemodialysis was diagnosed with diffuse large B-cell lymphoma in the kidney.
- Treatment with a modified R-CHOP regimen led to partial remission and no tumor progression at 15-month follow-up.
- Primary renal lymphoma can mimic renal cell carcinoma, requiring imaging and biopsy for accurate diagnosis.

## Abstract

Primary renal lymphoma is a rare renal malignancy, and its occurrence in patients undergoing maintenance haemodialysis is even more uncommon. Herein, we report the case of a 57-year-old woman undergoing maintenance haemodialysis, presenting with gross haematuria. After performing enhanced magnetic resonance imaging, positron emission tomography-computed tomography, and a kidney biopsy, a diffuse large B-cell lymphoma was detected. She was subsequently treated with five cycles of a modified R-CHOP regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and achieved partial remission, as evidenced by an abdominal computed tomography scan. At the 15-month follow-up, no further enlargement or metastasis of the residual tumour was evident. We emphasize that the clinical manifestations of primary renal lymphoma (PRL) resemble those of renal cell carcinoma, necessitating an imaging and biopsy-based differential diagnosis to avoid misdiagnosis. Although PRL has a highly aggressive phenotype and is associated with high mortality, early diagnosis and appropriate treatment can improve patient outcomes.

## Linked entities

- **Chemicals:** cyclophosphamide (PubChem CID 2907), doxorubicin (PubChem CID 31703), vincristine (PubChem CID 5978), prednisone (PubChem CID 5865)
- **Diseases:** diffuse large B-cell lymphoma (MONDO:0018905), renal cell carcinoma (MONDO:0005086)

## Full-text entities

- **Diseases:** renal cell carcinoma (MESH:D002292), B-cell lymphoma (MESH:D016393), renal malignancy (MESH:D009369), uremic (MESH:D006463), PRL (MESH:D008223)
- **Chemicals:** rituximab (MESH:D000069283), R-CHOP (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12118068/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12118068/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12118068/full.md

---
Source: https://tomesphere.com/paper/PMC12118068